Company intelligence / Profile preview
CaroGen Corporation
Farmington, Connecticut, USAcarogencorp.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Preclinical
01
Overview
Two candidates in late stage pre-clinical (IND enabling) studies: CARG-2020 for ovarian cancer and CARG-201 for Chronic Hepatitis B. HBV program supported by over $16 million in NIH & DoD grants.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccinesImmunotherapyRNA-based therapiesVirus-like vesicles (VLVs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
NIHDoDWayne State UniversityUConn Health
Beyond the preview
Go deeper on CaroGen Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CaroGen Corporation.